Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 39%
Buy 61%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is well-positioned for growth with strong financials, FDA approval, and expansion plans in multiple markets. Their inclusion in ACS guidelines and plans to offer testing for a wider range of tumor types and lower costs by 2028 provide a solid foundation for future success. However, the company should closely monitor competition in the precision oncology diagnostics market and ensure successful launches of new tests.

Bears say

Guardant Health is facing several risks that could potentially impact its growth and profitability. These include potential market maturation and saturation, uncertainty surrounding future recommendations from the U.S. Preventative Services Task Force, and concerns about competition and potential litigation in the precision oncology space. While Guardant has shown impressive growth so far, there are potential challenges ahead, such as the risk of overvaluation and volatility in the precision oncology market and the company's reliance on a few key products and partnerships. Additionally, there are potential risks in the company's development, reimbursement, and commercialization strategies for its new MRD and early detection tests.

GH has been analyzed by 23 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 61% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 23 analysts, GH has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.